Labcorp Holdings Inc Stock Price, News & Analysis

Labcorp (NYSE: LH) has achieved IVDR CE-marking for its PGDx elio tissue complete test in the European Union, making it the first and only test of its kind approved for comprehensive solid tumor profiling under new EU regulations. The test, which already has FDA clearance in the US, will help diagnose and treat approximately 2.7 million people diagnosed with cancer annually in the EU.

The in vitro diagnostic assay can analyze multiple biomarkers simultaneously, even with limited tissue samples, enabling faster and more effective patient management plans. The test will be available through Labcorp's central laboratory in Geneva, Switzerland, supporting both biopharma partners and investigational use in global clinical trials.

Labcorp (NYSE: LH) reported strong Q2 2025 results with revenue of $3.53 billion, up 9.5% from Q2 2024. The company achieved diluted EPS of $2.84 and adjusted EPS of $4.35, marking a 10.4% increase year-over-year.

Based on strong performance, Labcorp raised its full-year 2025 guidance, with revenue growth now expected at 7.5% to 8.6%, adjusted EPS range of $16.05 to $16.50, and free cash flow projected between $1.13-$1.28 billion. The company expanded through strategic acquisitions, including assets from Incyte Diagnostics and BioReference Health, while launching innovative oncology tests and expanding its consumer offerings.

The company maintained its shareholder returns with a $0.72 quarterly dividend and $200 million in share repurchases during Q2.

Community Health Systems (NYSE:CYH) has entered into a definitive agreement to sell select ambulatory outreach laboratory assets to Labcorp (NYSE:LH) for $195 million in cash. The transaction covers laboratory services across 13 states, including patient service centers and in-office phlebotomy locations.

CHS will retain operation of inpatient and emergency department laboratories while continuing to provide hospital-based laboratory services. The deal aims to provide broader access to Labcorp's comprehensive testing services, specialty testing menu, data analytics, and digital tools. The transaction is expected to close in Q4 2025, subject to regulatory approvals.

Labcorp (NYSE:LH), a leading global laboratory services provider, has announced a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on September 11, 2025, to shareholders of record as of August 28, 2025.

Labcorp (NYSE:LH), a leading provider of innovative laboratory services, has scheduled its Q2 2025 financial results announcement for July 24, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM ET to discuss the results.

Investors can access the earnings release and financial information on Labcorp's Investor Relations website. A webcast replay will be available approximately two hours after the event until July 11, 2026.

Labcorp (NYSE: LH) has launched Labcorp Whole Health Solutions, a comprehensive testing service designed for functional medicine, integrative medicine, and primary care providers. The offering includes specialized test panels and over 1,000 scientifically backed biomarkers focusing on cardiometabolic health, hormones, micronutrients, longevity, and wellness. The service features seven distinct panels including Advanced Cardiometabolic, Comprehensive Nutrient, Longevity and Vitality, and gender-specific hormone and wellness panels. This launch addresses growing market demand, with NIH data showing 37% of U.S. adults (122 million people) used complementary or integrative health approaches in 2022. Patients can access these services through physician offices or Labcorp's network of 2,200+ patient service centers nationwide.

Labcorp (NYSE: LH) has announced a significant expansion of its precision oncology portfolio, introducing new diagnostic solutions and enhanced biopharma services. The company launched new NGS panels for blood cancers, a Rapid AML Panel, and expanded its OmniSeq INSIGHT test to include HRD testing. The expansion includes FDA-approved companion diagnostics for breast and lung cancer patients, and advancements in digital pathology. On the biopharma front, Labcorp is expanding its Plasma Focus liquid biopsy test globally to Geneva and Shanghai, complementing its Tissue Complete assay. The company has also launched an enhanced digital pathology platform using Leica Biosystems scanners and Proscia's Concentriq LS system for improved clinical trials and companion diagnostic development.

SOLVD Health has strengthened its Board of Directors with the appointments of Mike Aicher and Vince Cebula. Aicher, a diagnostics pioneer with over 30 years of executive experience, co-founded National Genetics Institute (acquired by Labcorp) and previously led Labcorp's Esoteric Business Units, generating over $1 billion in annual revenue. Cebula brings extensive financial expertise from roles at Oaktree Capital Management and Jefferies Capital Partners.

These strategic appointments come as SOLVD Health advances its proprietary diagnostics platform, including the FDA-approved AvertD® test for assessing genetic risk of opioid use disorder (OUD). The company aims to expand its personalized health solutions and precision diagnostics platform to deliver better health outcomes through data-driven innovation.

Labcorp (NYSE: LH), a leading global laboratory services provider, has announced that its Annual Meeting of Shareholders will be held virtually on May 15 at 9:00 a.m. ET. Shareholders and interested parties can access the live webcast through the company's Investor Relations website. The recorded session will remain available for replay for one year following the meeting.